PD22-07 A META-ANALYSIS OF LONG ACTING VERSUS SHORT ACTING PHOSPHODIESTERASE 5 INHIBITORS: COMPARISION BETWEEN THE COMBINATION USE WITH ALPHA-BLOCKERS AND ALPHA-BLOCKER MONOTHERAPHY.

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Medical & Non-surgical Therapy1 Apr 2016PD22-07 A META-ANALYSIS OF LONG ACTING VERSUS SHORT ACTING PHOSPHODIESTERASE 5 INHIBITORS: COMPARISION BETWEEN THE COMBINATION USE WITH ALPHA-BLOCKERS AND ALPHA-BLOCKER MONOTHERAPHY. HOON CHOI, Ji Sung Shim, Seung Min Jeong, Jae Young Park, Du Geon Moon, Jeong Gu Lee, and Jae Hyun Bae HOON CHOIHOON CHOI More articles by this author , Ji Sung ShimJi Sung Shim More articles by this author , Seung Min JeongSeung Min Jeong More articles by this author , Jae Young ParkJae Young Park More articles by this author , Du Geon MoonDu Geon Moon More articles by this author , Jeong Gu LeeJeong Gu Lee More articles by this author , and Jae Hyun BaeJae Hyun Bae More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.1500AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES A number of clinical trials on combination medication of a1-adrenergic blocker and phosphodiesterase type 5 inhibitors (PDE5-Is) have showed improvements in lower urinary tract symptoms (LUTS) with negligible side effects. Nontheless, decisive advantage in various clinical parameters associated with symptom improvement were insufficient, and the clinical differences in long acting versus short acting PDE5-Is in the combination use with alpha-blockers and alpha-blocker monotheraphy are lacking. METHODS Data search was conducted through the Medline, Embase, Cochrane Library databases and KoreaMed through 2000 to 2014 including the combination of the following terms: a-blockers, a1-adrenergic blocker, LUTS, BPH, ED. PDE5-Is included sildena?l, vardena?l, mirodenafil as a short acting and tadala?l as a long acting agent. RESULTS Among 323 relevant references, 10 were selected for meta-analysis. The 616 men received combination medication (PDE5-Is with a1-adrenergic blockers) or only a1-adrenergic blocker monotheraphy. Meta-analysis of the combination medication showed more effectiveness than alpha-blocker in improving symptoms, so mean IPSS change difference was -1.93 and long acting versus short acting PDE5-I were -2.12 versus -1.70. Q-max was more increased in combination medication with mean difference of 0.71 and change were 0.14 in long acting, 1.13 in short acting PDE5-I. Residual urine was more decreased in combination medication than a1- monotheraphy with mean difference of -7.09, and the mean residual urine change in long acting versus short acting PDE5-I were -18.83 versus -5.93. The IIEF was increased in combination medication patients by 3.99: Long acting PDE5-I by 2.85 and short acting PDE5-I by 4.85. CONCLUSIONS The meta-analysis of the accessible studies advocates that PDE5-Is can signi?cantly improve LUTS in men with BPH/ED. PDE5-Is with a1-adrenergic blockers could be a more effective short-term treatment than a1-adrenergic blocker monotheraphy for patients with LUTS and ED with minimal differences between the long acting and short acting agent. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e463-e464 Advertisement Copyright & Permissions© 2016MetricsAuthor Information HOON CHOI More articles by this author Ji Sung Shim More articles by this author Seung Min Jeong More articles by this author Jae Young Park More articles by this author Du Geon Moon More articles by this author Jeong Gu Lee More articles by this author Jae Hyun Bae More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...